Meta-analysis of association between cytokine gene polymorphisms and Behcet's disease risk

2013 ◽  
Vol 16 (6) ◽  
pp. 616-624 ◽  
Author(s):  
Yan Liang ◽  
Wang-Dong Xu ◽  
Min Zhang ◽  
Li-Juan Qiu ◽  
Jing Ni ◽  
...  
2020 ◽  
Vol 2020 ◽  
pp. 1-17
Author(s):  
Xue-Feng Li ◽  
Zhi-Zhen Huang ◽  
Yuan-Yuan Hu ◽  
Yu-Ming Niu ◽  
Jun-Wei Cai

Epidemiological studies have demonstrated that interleukin-10 (IL-10) polymorphisms may be associated with the development of Behcet’s disease (BD). However, the published results were inconsistent. Therefore, this meta-analysis was conducted to derive a more precise relationship between IL-10 polymorphisms and BD susceptibility. Online databases (PubMed, Embase, Science Citation Index (SCI), CNKI, and WanFang) were searched to identify eligible studies. Odds ratio (OR) and a 95% confidence interval (CI) were applied to assess the relationship strength between IL-10 -1082A>G (rs1800896), -819T>C (rs1800871), and -592A>C (rs1800872) polymorphisms and BD susceptibility. Publication bias, sensitivity, and cumulative analyses were conducted to measure the robustness of our findings. Finally, fifteen articles (36 independent case-control studies) involving 5,971 patients and 8,913 controls were included. Overall, significant associations between -819T>C polymorphisms and BD risk were observed in the total population (C vs. T: OR=0.72, 95%CI=0.67‐0.77, P<0.01, I2=36.6%; TC vs. TT: OR=0.73, 95%CI=0.66‐0.80, P<0.01, I2=23.0%; CC vs. TT: OR=0.52, 95%CI=0.39‐0.70, P<0.01, I2=53.7%; TC+CC vs. TT: OR=0.67, 95%CI=0.61‐0.71, P<0.01, I2=22.1%; and CC vs. TT+TC: OR=0.66, 95%CI=0.53‐0.82, P<0.01, I2=57.8%). Moreover, the IL-10 -592 A>C polymorphism and the ACC haplotype exhibited a significant, protective effect against BD susceptibility. In summary, our meta-analysis suggested that IL-10 gene polymorphisms may play a salient role for BD development.


2015 ◽  
Vol 164 (1) ◽  
pp. 18-24 ◽  
Author(s):  
Abir Naouali ◽  
Wajih Kaabachi ◽  
Kalthoum Tizaoui ◽  
Amira Ben Amor ◽  
Agnès Hamzaoui ◽  
...  

2011 ◽  
Vol 38 (4) ◽  
pp. 295-301 ◽  
Author(s):  
A. A. Özçimen ◽  
K. Dilek ◽  
Ü. Bingöl ◽  
H. Sarıcaoğlu ◽  
A. Sarandöl ◽  
...  

2009 ◽  
Vol 30 (2) ◽  
pp. 285-289 ◽  
Author(s):  
Mortaza Bonyadi ◽  
Zohreh Jahanafrooz ◽  
Mohsen Esmaeili ◽  
Susan Kolahi ◽  
Alireza Khabazi ◽  
...  

2014 ◽  
Vol 35 (3) ◽  
pp. 471-477 ◽  
Author(s):  
Suleyman Serdar Koca ◽  
Murat Kara ◽  
Firat Deniz ◽  
Metin Ozgen ◽  
Caner Feyzi Demir ◽  
...  

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Tim T. A. Bender ◽  
Judith Leyens ◽  
Julia Sellin ◽  
Dmitrij Kravchenko ◽  
Rupert Conrad ◽  
...  

Abstract Background Rare diseases (RDs) in rheumatology as a group have a high prevalence, but randomized controlled trials are hampered by their heterogeneity and low individual prevalence. To survey the current evidence of pharmacotherapies for rare rheumatic diseases, we conducted a systematic review and meta-analysis. Randomized controlled trials (RCTs) of RDs in rheumatology for different pharmaco-interventions were included into this meta-analysis if there were two or more trials investigating the same RD and using the same assessment tools or outcome parameters. The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PUBMED were searched up to April 2nd 2020. The overall objective of this study was to identify RCTs of RDs in rheumatology, evaluate the overall quality of these studies, outline the evidence of pharmacotherapy, and summarize recommended therapeutic regimens. Results We screened 187 publications, and 50 RCTs met our inclusion criteria. In total, we analyzed data of 13 different RDs. We identified several sources of potential bias, such as a lack of description of blinding methods and allocation concealment, as well as small size of the study population. Meta-analysis was possible for 26 studies covering six RDs: Hunter disease, Behçet’s disease, giant cell arteritis, ANCA-associated vasculitis, reactive arthritis, and systemic sclerosis. The pharmacotherapies tested in these studies consisted of immunosuppressants, such as corticosteroids, methotrexate and azathioprine, or biologicals. We found solid evidence for idursulfase as a treatment for Hunter syndrome. In Behçet’s disease, apremilast and IF-α showed promising results with regard to total and partial remission, and Tocilizumab with regard to relapse-free remission in giant cell arteritis. Rituximab, cyclophosphamide, and azathioprine were equally effective in ANCA-associated vasculitis, while mepolizumab improved the efficacy of glucocorticoids. The combination of rifampicin and azithromycin showed promising results in reactive arthritis, while there was no convincing evidence for the efficacy of pharmacotherapy in systemic sclerosis. Conclusion For some diseases such as systemic sclerosis, ANCA-associated vasculitis, or Behcet's disease, higher quality trials were available. These RCTs showed satisfactory efficacies for immunosuppressants or biological drugs, except for systemic sclerosis. More high quality RCTs are urgently warranted for a wide spectrum of RDs in rheumatology.


2009 ◽  
Vol 70 (1) ◽  
pp. 41-44 ◽  
Author(s):  
Ryuichi Tomiyama ◽  
Akira Meguro ◽  
Masao Ota ◽  
Yoshihiko Katsuyama ◽  
Tadayuki Nishide ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document